Figure 1.
Summary of FVIII activity, ALT, AST, and corticosteroid dosing for individual participants in cohort 4 (giroctocogene fitelparvovec dose: 3 × 1013 vg/kg). Administration of corticosteroids (start and end) is shown for participants 7 (A), 8 (B), 9 (C), 10 (D), and 11 (E); participant 9 did not use glucocorticoids. Elevations in liver enzymes were managed with corticosteroids, with stabilization of transaminase levels and FVIII activity observed over time.